# Synergistic enhancement of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 -mediated gene editing in porcine zygotes through combined lipofection and electroporation of cationic lipid-packaged ribonucleoproteins

**Authors:** Qingyi Lin, Takeshige Otoi, Oky Setyo Widodo, Theerawat Tharasanit, Kaywalee Chatdarong, Zhao Namula, Maki Hirata, Aya Nakai, Yuichiro Nakayama, Megumi Nagahara, Fuminori Tanihara

PMC · DOI: 10.14202/vetworld.2025.3806-3814 · Veterinary World · 2025-12-10

## TL;DR

This study shows that combining lipofection and electroporation improves CRISPR gene editing in pig embryos without harming their development.

## Contribution

The novel contribution is demonstrating that sequential lipofection followed by electroporation enhances CRISPR efficiency in porcine zygotes.

## Key findings

- Blastocyst formation rates were comparable across all treatments, indicating no cytotoxicity.
- TL + EPL treatment significantly increased mutation rates for B4GALNT2 and GHR genes.
- Pre-EP lipofection promotes RNP uptake by enhancing lipid-membrane interactions.

## Abstract

Genetically engineered pigs are invaluable biomedical models for xenotransplantation and the study of human diseases. Although electroporation (EP) and lipofection are individually effective for clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) ribonucleoprotein (RNP) delivery, their combined application in porcine embryos has not been systematically evaluated. This study aimed to determine whether packaging Cas9-guided RNA complexes in cationic lipids enhances EP-mediated gene editing efficiency without compromising embryonic development.

Porcine zygotes with their zona pellucida removed were edited using RNPs targeting beta-1,4-N-acetyl-galactosaminyl transferase 2 (B4GALNT2) or growth hormone receptor (GHR) genes. Four treatment groups were tested: (1) EP with RNPs (EP), (2) EP with lipofectamine-packaged RNPs (EPL), (3) transfection with lipofectamine-packaged RNPs before EP (TL + EPL), and (4) EP followed by lipofection (EPL + TL). Blastocyst formation was evaluated morphologically, and mutation rates were assessed by Sanger sequencing followed by tracking of indels by decomposition (TIDE) analysis.

Blastocyst formation rates were comparable across all treatments, indicating that lipofectamine packaging and EP caused no detectable cytotoxicity. For B4GALNT2, no mutations were induced by EP alone, whereas TL + EPL treatment significantly increased total and mosaic mutation rates (p < 0.05). For GHR, the total mutation and mosaic mutation rates were likewise higher in TL + EPL compared with EP, although mutation efficiency (indel percentage per edited embryo) remained unchanged. These results suggest that pre-EP lipofection promotes RNP uptake by facilitating lipid-membrane interactions that are potentiated by subsequent membrane destabilization through EP.

Packaging RNPs in cationic lipids and applying sequential lipofection followed by EP significantly enhances CRISPR/Cas9-mediated mutagenesis in porcine zygotes without affecting developmental competence. This dual-delivery approach provides a simple, reproducible, and low-toxicity workflow for generating gene-edited embryos, with potential applicability to large-animal biomedical models.

## Linked entities

- **Genes:** B4GALNT2 (beta-1,4-N-acetyl-galactosaminyltransferase 2 (SID blood group)) [NCBI Gene 124872], GHR (growth hormone receptor) [NCBI Gene 2690]
- **Proteins:** cas9 (type II CRISPR RNA-guided endonuclease Cas9)
- **Chemicals:** lipofectamine (PubChem CID 100984821)

## Full-text entities

- **Genes:** GHR (growth hormone receptor) [NCBI Gene 2690] {aka GHBP, GHIP}, GHR (growth hormone receptor) [NCBI Gene 397488], EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, RNPC3 (RNA binding region (RNP1, RRM) containing 3) [NCBI Gene 55599] {aka CPHD7, IGHD5, RBM40, RNP, SNRNP65}, B4GALNT2 (beta-1,4-N-acetyl-galactosaminyltransferase 2 (SID blood group)) [NCBI Gene 124872] {aka B4GALT, GALGT2}, HEPHL1 (hephaestin like 1) [NCBI Gene 341208] {aka HJDD, ZP}, B4GALNT2 (beta-1,4-N-acetyl-galactosaminyltransferase 2 (SID blood group)) [NCBI Gene 100621328]
- **Diseases:** cytotoxic (MESH:D064420), Laron syndrome (MESH:D046150)
- **Chemicals:** PFM (MESH:C044626), mineral oil (MESH:D008899), Lipofectamine 2000 (MESH:C086724), Earle's salts (-), saline (MESH:D012965), gentamicin (MESH:D005839), NaOH (MESH:D012972), D-sorbitol (MESH:D013012), water (MESH:D014867), TL (MESH:D013793), CO2 (MESH:D002245), lipid (MESH:D008055), cysteine (MESH:D003545), agarose (MESH:D012685)
- **Species:** Homo sapiens (human, species) [taxon 9606], Sus scrofa (pig, species) [taxon 9823]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12913885/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12913885/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC12913885/full.md

---
Source: https://tomesphere.com/paper/PMC12913885